𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Adverse effects of treatment with intravenous immunoglobulins for neurological diseases

✍ Scribed by Matthias Wittstock; Uwe K. Zettl


Publisher
Springer
Year
2006
Tongue
English
Weight
185 KB
Volume
253
Category
Article
ISSN
0340-5354

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Effect of high-dose intravenous immunogl
✍ Boyd M. Koffman; Marinos C. Dalakas πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 52 KB πŸ‘ 2 views

The effect of intravenous immunoglobulin (IVIG) on various laboratory values was measured immediately before and after completion of serial monthly infusions of IVIG (2 g/kg) or an equal volume of placebo over 3-12 months, in 46 patients with neuromuscular diseases participating in controlled trials

Effect of treatment with intravenous imm
✍ Willibald Gerschlager; Peter Brown πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 53 KB

The therapeutic effects of intravenous immunoglobulin (IVIG) on the stiff-person syndrome (SPS) have been described exclusively in case reports or open-label studies in terms of clinical outcomes. We investigate whether IVIG improves quality of life (QoL) in the SPS. Six patients with the classic fo

Failure of low-dose intravenous immunogl
✍ Keith S. Kanik; Cheryl H. Yarboro; Yaakov Naparstek; Paul H. Plotz; Ronald L. Wi πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 262 KB πŸ‘ 2 views

Treatment with high-dose (400 mg/kg/ day) intravenous immunoglobulin ( M g ) shows benefit in many autoimmune diseases but is very expensive. Low-dose M g has also been shown to be effective in inhibiting adjuvant arthritis in the rat. This pilot, randomized, double-blind, placebo-controlled trial w

Usefulness of a low-dose intravenous imm
✍ Majluf-Cruz, Abraham; Luna-CastaΓ±os, GermΓ‘n; HuitrΓ³n, Soledad; Nieto-Cisneros, L πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 41 KB πŸ‘ 2 views

Infection with the human immunodeficiency virus (HIV) frequently is complicated with thrombocytopenia (HIV-Thr) during all stages of the infection. The treatments for autoimmune thrombocytopenic purpura (ITP) are used in HIV-Thr; however, their effects upon the immune status of patients with acquire